Hemostatic adhesive as well as preparation method and application thereof

Abstract

The invention relates to a hemostatic adhesive as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The hemostatic adhesive comprises an aldehyde group modified polyethylene glycol high-molecular polymer, an amino high-molecular polymer and a thickening agent, the mass ratio of the aldehyde group modified polyethylene glycol high-molecular polymer to the amino high-molecular polymer to the thickening agent is 1: (0.2-20): (0.1-10). The hemostatic adhesive prepared by the invention is obtained through in-situ polymerization, is easy to inject, and can flow into and fill tissue gaps after injection to complete hemostatic packing; the hemostatic adhesive is high in gel forming speed, can be quickly adhered to the surface of a wound surface when acting on the wound surface, and does not fall off; the hemostatic adhesive physically isolates a wound from the external environment in the wound healing process, prevents wound infection, can be gradually degraded in vivo within 7-10 days, and is non-toxic and harmless.

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to a hemostatic adhesive and a preparation method and application thereof. Background Art

[0002] Medical hemostatic sealants have been widely used in trauma surgery, which can greatly reduce intraoperative bleeding and postoperative complications, thereby improving surgical results. However, for patients taking oral anticoagulants, medical sealants must have higher requirements, requiring them to be able to stop bleeding under anticoagulant conditions, and requiring the hemostatic materials to be safe and easy to remove, in addition to having certain price advantages.

[0003] At present, the main hemostatic agent used in traumatic organ hemostasis is fibrin glue, which mainly relies on prothrombin and fibrinogen, while anticoagulants such as heparin easily interfere with or quench thrombin, making fibrin glue unable to meet the hemostasis requirements of anticoagulated patients. In view of this, the present invention provides a hemostatic adhesive and its preparation method and application. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a hemostatic adhesive and its preparation method and application, with the aim of providing a safe, stable, biocompatible hemostatic adhesive that is not affected by anticoagulants, has non-toxic and harmless degradation products, and is safe and reliable.

[0005] The technical solution of the present invention to solve the above technical problems is as follows: In a first aspect, a hemostatic adhesive comprises an aldehyde-modified polyethylene glycol polymer, an amino polymer and a thickener; the mass ratio of the aldehyde-modified polyethylene glycol polymer, the amino polymer and the thickener is 1:(0.2-20):(0.1-10).

[0006] The beneficial effects of the present invention are: (1) The raw materials used to prepare the hemostatic adhesive of the present invention are simple and easy to obtain, and have good biocompatibility; it is prepared by Schiff base reaction, has a fast reaction, does not use a cross-linking agent, and has high biosafety.

[0007] (2) The hemostatic adhesive prepared by the present invention is obtained by in-situ polymerization and is easy to inject. After injection, it can flow into and fill the tissue gap to complete hemostatic packing. The hemostatic adhesive has a fast gelling speed. When acting on the wound surface, it will quickly adhere to the wound surface and will not fall off. During the wound healing process, the hemostatic adhesive physically isolates the wound from the external environment to prevent wound infection.

[0008] (3) The hemostatic adhesive of the present invention will gradually degrade in the body within 7-10 days and is non-toxic and harmless.

[0009] Based on the above technical solution, the present invention can also be improved as follows.

[0010] Furthermore, the aldehyde-modified polyethylene glycol polymer includes at least one of a propionaldehyde-modified polyethylene glycol polymer, a benzaldehyde-modified polyethylene glycol polymer, and a dialdehyde-modified polyethylene glycol polymer.

[0011] Furthermore, the propionaldehyde-modified polyethylene glycol polymer includes at least one of propionaldehyde-modified two-arm polyethylene glycol, four-arm polyethylene glycol, eight-arm polyethylene glycol and Y-shaped polyethylene glycol; the benzaldehyde-modified polyethylene glycol polymer includes at least one of benzaldehyde-modified two-arm polyethylene glycol, four-arm polyethylene glycol, eight-arm polyethylene glycol and Y-shaped polyethylene glycol; the dialdehyde-modified polyethylene glycol polymer is a single-arm linear polyethylene glycol; Among them, propionaldehyde-modified polyethylene glycol (PEG-pALD) is a polyethylene glycol derivative with a propionaldehyde functional group attached to the end; Propionaldehyde-modified eight-arm polyethylene glycol (8-arm-PEG--pALD) is a compound containing eight polyethylene glycol chains, each with a propionaldehyde functional group at the end; Propionaldehyde-modified Y-shaped polyethylene glycol (Y-shape PEG-CHO) is a compound with a Y-shaped polyethylene glycol chain with a propionaldehyde functional group at each end of the chain.

[0012] Benzaldehyde-modified polyethylene glycol (PEG-Benzaldehyde) is a polyethylene glycol derivative with benzaldehyde functional groups attached to both ends; Benzaldehyde-modified two-arm polyethylene glycol (2-arm-PEG-Benzaldehyde) is a compound containing two polyethylene glycol chains, each with a benzaldehyde functional group at the end.

[0013] Benzaldehyde-modified four-arm polyethylene glycol (4-arm-PEG-Benzaldehyde) refers to a compound in which benzaldehyde functional groups are connected to the four chain ends of the four-arm polyethylene glycol (4arm-PEG) molecule; OHC-PEG-CHO is a polyethylene glycol derivative with two aldehyde groups.

[0014] The amino polymer includes at least one of animal gelatin (derived from pig skin or fish skin), polypeptide, chitosan, carboxymethyl chitosan, polyethylene imine, and amino-modified polyethylene glycol derivatives; preferably, any one of polyethylene imine, gelatin, and carboxymethyl chitosan, or a combination of at least two thereof; The thickener includes at least one of cyclodextrin, hyaluronic acid and alginic acid.

[0015] The beneficial effects of adopting the above further scheme are: using multi-arm polyethylene glycol with aldehyde groups to react with the amino polymer to form a Schiff base, so that the formed three-dimensional structure has a higher degree of cross-linking and better mechanical strength; the amino polymer is degradable and can react with the aldehyde-modified polyethylene glycol polymer at room temperature; using a thickener to make its solution have a certain viscosity before gelation, so that it can stay on the wound surface during injection.

[0016] Furthermore, the hemostatic adhesive is formed by cross-linking the aldehyde-modified polyethylene glycol polymer, the amino polymer and the thickener.

[0017] In a second aspect, a method for preparing a hemostatic adhesive comprises the following steps: dissolving an aldehyde-modified polyethylene glycol polymer in a first solvent to obtain component A; dissolving an amino polymer and a thickener in a second solvent to obtain component B; and mixing the component A and the component B to obtain a hemostatic adhesive.

[0018] The beneficial effects of adopting the above scheme are: the preparation method of the hemostatic adhesive for promoting hemostasis and wound healing of the present invention is simple and stable to operate, plays an auxiliary role in the self-repair process of the human body, and has no unknown side effects in drug use.

[0019] Furthermore, the aldehyde-modified polyethylene glycol polymer is dissolved in a solvent, or the amino polymer and the thickener are dissolved in a solvent by stirring and dissolving. Specifically, the stirring and dissolving method is at least one of stirring and dissolving at room temperature, stirring and dissolving at 40-70°C, mechanical stirring and dissolving, vortex mixing and dissolving, and ultrasonic dissolving; preferably, at least one of stirring and dissolving at room temperature, stirring and dissolving at 40-70°C, and vortex mixing and dissolving.

[0020] Further, the first solvent includes at least one of double distilled water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution; The second solvent includes at least one of double distilled water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution.

[0021] Furthermore, the mass concentration of the aldehyde-modified polyethylene glycol polymer in component A is 0.1%-20%; the mass concentration of the amino polymer in component B is 0.01%-30%; and the mass concentration of the thickener in component B is 0.02%-20%.

[0022] Furthermore, the mass concentration of the aldehyde-modified polyethylene glycol polymer in component A is 0.5%-15%; the mass concentration of the amino polymer in component B is 0.05%-10%, and the mass concentration of the thickener in component B is 0.05%-5%.

[0023] Furthermore, the volume ratio of the component A to the component B is 1:1-5.

[0024] The beneficial effect of adopting the above further scheme is that the aldehyde-modified polyethylene glycol polymer, the amino polymer and the thickener undergo moderate cross-linking at a specific concentration to construct a hemostatic adhesive having both adhesion and continuous fluidity.

[0025] Furthermore, the solid content of the hemostatic adhesive is 1%-30%.

[0026] The beneficial effects of adopting the above further solution are: the hemostatic adhesive within this range has good adhesion and rapid in-situ gelation.

[0027] A third aspect provides an application of a hemostatic adhesive, wherein the hemostatic adhesive is used to prepare products for hemostasis and wound healing.

[0028] When the hemostatic adhesive for hemostasis and wound healing is used, each component is independently loaded in a double-barreled syringe, and is injected into the bleeding site of the internal organs or blood vessels through a premixed head. The hemostatic adhesive adheres to the surface of the wound, and achieves hemostasis through instant physical blocking and packing. At the same time, the wound is isolated from the outside world to promote healing. Specifically, after the completion of internal surgery, the fluid hemostatic adhesive is injected into the wound using a syringe, and injected in situ in a relatively low viscosity state, and the hemostatic adhesive state is quickly formed at body temperature, which can not only stop bleeding quickly, but also fill wounds of different shapes and sizes; after being injected into the wound, a cross-linking reaction quickly occurs to form a hemostatic adhesive. Since the hemostatic adhesive formed by the cross-linking reaction is a Schiff base reaction between the aldehyde group and the amino group, the hemostatic adhesive formed can be slowly degraded at the bleeding site, and finally the hemostatic adhesive state gradually changes into a fluid liquid, which is naturally discharged from the body in accordance with physiological conditions. The adaptability of this phase transition helps to integrate biological signals to promote tissue regeneration, filling the gap in the medical field of hemostasis and wound healing in domestic medical devices.

[0029] Furthermore, the hemostatic adhesive is used to prepare products for hemostasis and promoting wound healing in humans, mammals, birds and reptiles. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is the hemostatic adhesive prepared in Example 1 of the present invention.

[0031] Figure 2The first day effect of using rat wound samples.

[0032] Figure 3 This is the in vitro degradation cycle of Example 1 of the present invention in a PBS solution at 37°C in vitro.

[0033] Figure 4 This is a diagram showing the results of the skin embedding experiment of the hemostatic adhesive prepared in Example 1 of the present invention; wherein a is the state after three days of degradation, and b is the state after seven days of degradation.

[0034] Figure 5 The wound repair effect of the hemostatic adhesive sample prepared in Example 1 of the present invention on the 3rd day after use; wherein a is the blank group and b is the experimental group.

[0035] Figure 6 This is the wound repair effect of the hemostatic adhesive sample prepared in Example 1 of the present invention on the 7th day after use, wherein a is the wound of the blank group, and b is the wound of the experimental group. DETAILED DESCRIPTION

[0036] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0037] Sources of materials and reagents: Propionaldehyde-modified polyethylene glycol polymer, benzaldehyde-modified polyethylene glycol polymer and dialdehyde-modified polyethylene glycol polymer were all purchased from Xiamen Sinobond; gelatin (derived from pig skin or fish skin) was purchased from Sigma; chitosan was purchased from Qingdao Hydefeng; carboxymethyl chitosan was purchased from Qingdao Hydefeng; polyethyleneimine was purchased from McLean; hyaluronic acid was purchased from McLean; and cyclodextrin was purchased from McLean.

[0038] Example 1 The present embodiment relates to a method for preparing a hemostatic adhesive that stops bleeding and promotes wound healing, comprising the following steps: accurately weigh 220 mg of benzaldehyde-modified four-arm polyethylene glycol (4-arm-PEG-Benzaldehyde) in a centrifuge tube, add 2.08 g of deionized water to dissolve, and record it as component A; accurately weigh 200 mg of carboxymethyl chitosan and 50 mg of cyclodextrin in a sample bottle, add 5 g of deionized water, stir and dissolve at 40°C, and mark it as component B. Take a double-barreled syringe, load 1.0 mL of component A and component B respectively, mix them through the premixing head, and you can get a hemostatic adhesive that stops bleeding and promotes wound healing within 15 seconds at room temperature. The hemostatic adhesive prepared in this embodiment is as follows Figure 1Its components and gelling state are shown in Table 1.

[0039] Example 2 This embodiment relates to a method for preparing a hemostatic adhesive for hemostasis and wound healing, comprising the following steps: accurately weighing 110 mg of propionaldehyde-modified eight-arm polyethylene glycol (8-arm-PEG-pALD) in a centrifuge tube, adding 2 g of phosphate buffer to fully dissolve, and marking it as component A; accurately weighing 150 mg of chitosan and 100 mg of hyaluronic acid in a sample bottle, adding 3.28 g of bicarbonate buffer, stirring and dissolving at 50-60°C and marking it as component B. Take a double-barreled syringe, load 0.5 mL of component A and component B respectively, mix them thoroughly through the premixing head, and the hemostatic adhesive for hemostasis and wound healing can be obtained within 50 seconds at room temperature. Its components and gelation state are shown in Table 1.

[0040] Example 3 This embodiment relates to a method for preparing a hemostatic adhesive for hemostasis and wound healing, comprising the following steps: accurately weighing 176 mg of dialdehyde polyethylene glycol (OHC-PEG-CHO) in a centrifuge tube, adding 1.90 g of deionized water to fully dissolve the dialdehyde polyethylene glycol, and marking it as component A; accurately weighing 0.22 g of polypeptide and 0.1 g of hyaluronic acid in a sample bottle, adding 6.5 g of deionized water, stirring and dissolving at 50°C-60°C, and marking it as component B. Take a double-barreled syringe and draw 2 mL of component A and 1 mL of component B respectively, mix them thoroughly through the premixing head, and the hemostatic adhesive for hemostasis and wound healing can be obtained within 45 seconds at room temperature. Its components and gel state are shown in Table 1.

[0041] Example 4 The present embodiment relates to a method for preparing a hemostatic and wound healing hemostatic adhesive, comprising the following steps: accurately weighing 0.10 g of benzaldehyde-modified two-arm polyethylene glycol (2-arm-PEG-Benzaldehyde) in a centrifuge tube, adding 1.6 g of deionized water, vortexing to fully dissolve the benzaldehyde-modified two-arm polyethylene glycol, and marking it as component A; accurately weighing 0.10 g of a 50 wt% polyethyleneimine aqueous solution and 0.01 g of hyaluronic acid in a sample bottle, adding 9.90 g of deionized water, mixing, dispersing and shaking, and setting aside. Take a double-barreled syringe and draw 1 mL of component A and 1 mL of component B respectively, mix them thoroughly through the premixing head, and the hemostatic and wound healing hemostatic adhesive can be obtained within 20 seconds at room temperature. Its components and gelling state are shown in Table 1.

[0042] Example 5 This embodiment relates to a method for preparing a hemostatic adhesive for hemostasis and wound healing, comprising the following steps: weighing 600 mg of propionaldehyde-modified four-arm polyethylene glycol (4arm-PEG-pLAD) in a centrifuge tube, adding 4.8 g of phosphate buffer solution to dissolve, and recording as component A; accurately weighing 250 mg of polypeptide and 50 mg of hyaluronic acid in a sample bottle, adding 5 g of bicarbonate buffer, stirring and dissolving at 40°C, and marking as component B. Take a double-barreled syringe, load 1.0 mL of component A and component B respectively, mix through the premixing head, gel in about 1 minute, the gelation speed slows down, and the strength weakens. Its components and gelation state are shown in Table 1.

[0043] Comparative Example 1 This comparative example relates to a method for preparing a hemostatic adhesive for hemostasis and wound healing, comprising the following steps: accurately weighing 10 mg of benzaldehyde-modified four-arm polyethylene glycol (4-arm-PEG-Benzaldehyde) in a centrifuge tube, adding 15 g of deionized water to dissolve, and recording as component A; accurately weighing 5 mg of carboxymethyl chitosan and 5 mg of cyclodextrin in a sample bottle, adding 55 g of deionized water, stirring and dissolving at 40°C, and marking as component B. Take a double-barreled syringe, load 1.0 mL of component A and component B respectively, mix through a premixing head, and cannot gel at room temperature for 1 minute. Its components and gelation state are shown in Table 1.

[0044] Comparative Example 2 This comparative example relates to a method for preparing a hemostatic adhesive for hemostasis and wound healing, comprising the following steps: accurately weighing 220 mg of carbonate-modified four-arm polyethylene glycol (4-arm-PEG-SC) in a centrifuge tube, adding 2.08 g of deionized water to dissolve, and recording as component A; accurately weighing 200 mg of carboxymethyl chitosan and 50 mg of cyclodextrin in a sample bottle, adding 5 g of deionized water, stirring and dissolving at 40°C, and marking as component B. Take a double-barreled syringe, load 1.0 mL of component A and component B respectively, mix through a premixing head, gel at room temperature for 2 min, and fail to complete hemostatic bonding. Its components and gelation state are shown in Table 1.

[0045] Comparative Example 3 This comparative example relates to a method for preparing a hemostatic adhesive for hemostasis and wound healing, comprising the following steps: accurately weighing 220 mg of formaldehyde, adding 2.08 g of deionized water to a centrifuge tube for dissolution, and recording as component A; accurately weighing 200 mg of carboxymethyl chitosan and 50 mg of cyclodextrin, adding 5 g of deionized water to a sample bottle, stirring and dissolving at 40°C, and recording as component B. Take a double-barreled syringe, respectively load 1.0 mL of component A and component B, mix through a premixing head, and cannot gel at room temperature, and cannot complete hemostasis and bonding. Its components and gelation state are shown in Table 1.

[0046] Comparative Example 4 This comparative example relates to a method for preparing a hemostatic adhesive for hemostasis and wound healing, comprising the following steps: accurately weighing 220 mg of benzaldehyde-modified four-arm polyethylene glycol (4-arm-PEG-Benzaldehyde) in a centrifuge tube, adding 2.08 g of deionized water to dissolve, and recording as component A; accurately weighing 200 mg of carboxymethyl chitosan in a sample bottle, adding 5 g of deionized water, stirring and dissolving at 40°C, and marking as component B. Take a double-barreled syringe, load 1.0 mL of component A and component B respectively, mix through a premixing head, and gel at room temperature for 30 s, but the initial fluidity of the injection is too strong and is easily washed away by the blood flow, so it cannot stop bleeding well. Its components and gelation state are shown in Table 1.

[0047] Test example (1) In vitro degradation experiment Accurately weigh five portions of 150 mg of the hemostatic adhesive prepared in Example 1 into a 50 mL centrifuge tube, add 100 times the volume of a PBS aqueous solution with a pH value of about 7.4, and place each of the centrifuge tubes in a constant temperature shaking water bath at 37°C and a shaking speed of 150 rpm / min. Shake to degrade, and record the mass of the hemostatic adhesive every 24 hours. Before weighing, use filter paper to absorb the moisture on the surface of the hemostatic adhesive. The results are as follows: Figure 3 shown.

[0048] Depend on Figure 3 It can be seen that the hemostatic adhesive reaches saturation in water absorption after 6 days of in vitro degradation, and is maintained at this water absorption multiple for 48 hours before degradation, and is completely degraded after 9 days of full degradation.

[0049] (2) Degradation of hemostatic adhesives in SD rats The hemostatic adhesive prepared in Example 1 was prepared by mixing component A and component B into a gel for 3-10 seconds. After the rat was anesthetized with isoflurane, an opening of about 1 cm was made subcutaneously on the back, and 50 mg of the hemostatic adhesive was placed. The wound was then sutured and the degradation of the hemostatic adhesive under the skin of the SD rat was observed. The results were shown in Figure 2 and Figure 4 As shown in ab.

[0050] Depend on Figure 2 and Figure 4 It can be concluded that the hemostatic adhesive prepared in Example 1 will be completely degraded after 7 days in the subcutaneous tissue of SD rats, and the subcutaneous state of the SD rats after degradation is almost the same as the subcutaneous appearance of the SD rats that have not been injected with the hemostatic adhesive.

[0051] (3) Effect of hemostatic adhesive on the healing of epidermal wounds in SD rats on day 3 The method for preparing a hemostatic adhesive in Example 1 was used. After component A and component B were mixed into a gel for 3-10 seconds, the rat was anesthetized with isoflurane, and a subcutaneous opening of about 0.5 cm was made on the back. 50 mg of hemostatic adhesive was placed on one side, and the other side was not treated as a control group. The healing of the epidermal wound of the SD rats on the 3rd day was observed. The healing of the blank group on the 3rd day is shown in 5a, and the healing of the experimental group on the 3rd day is shown in 5b.

[0052] Depend on Figure 5 From ab, it can be concluded that the hemostatic adhesive prepared in Example 1, Figure 5 Comparison between medium and b Figure 5 Middle a: The epidermal wound of SD rats healed rapidly on the 3rd day.

[0053] (4) Effect of hemostatic adhesive on the healing of epidermal wounds in SD rats on day 7 Depend on Figure 6 It can be concluded from Figures ab that the hemostatic adhesive prepared in Example 1 has basically healed the rat epidermal wound on the 7th day, and the healing condition of the left experimental group is better than that of the right blank group.

[0054] The components and gelling states of Examples 1 to 5 and Comparative Examples 1 to 4 are shown in Table 1.

[0055] Table 1 In summary, the raw materials used to prepare the hemostatic adhesive of the present invention are simple and easy to obtain, and have good biocompatibility; the hemostatic adhesive is prepared by Schiff base reaction, the reaction is fast, no cross-linking agent is used, and the biosafety is high.

[0056] The hemostatic adhesive prepared by the present invention is obtained by in-situ polymerization, is easy to inject, and can flow into and fill the tissue gap after injection to complete hemostatic packing; the hemostatic adhesive has a fast gelling speed, and when acting on the wound surface, it will quickly adhere to the wound surface and will not fall off; the hemostatic adhesive physically isolates the wound from the external environment during the wound healing process to prevent wound infection. The hemostatic adhesive of the present invention will gradually degrade in the body within 7-10 days and is non-toxic and harmless.

[0057] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A hemostatic adhesive, characterized in that: The hemostatic adhesive comprises an aldehyde-modified polyethylene glycol polymer, an amino polymer and a thickener; the mass ratio of the aldehyde-modified polyethylene glycol polymer, the amino polymer and the thickener is 1:(0.2-20):(0.1-10).

2. A hemostatic adhesive according to claim 1, characterized in that: The aldehyde-modified polyethylene glycol polymer includes at least one of a propionaldehyde-modified polyethylene glycol polymer, a benzaldehyde-modified polyethylene glycol polymer, and a dialdehyde-modified polyethylene glycol polymer; The amino polymer includes at least one of animal gelatin, polypeptide, chitosan, carboxymethyl chitosan, polyethyleneimine, and amino-modified polyethylene glycol derivatives; The thickener includes at least one of cyclodextrin, hyaluronic acid and alginic acid.

3. A hemostatic adhesive according to claim 1, characterized in that: The hemostatic adhesive is formed by cross-linking the aldehyde-modified polyethylene glycol macromolecular polymer, the amino macromolecular polymer and the thickener.

4. A method for preparing a hemostatic adhesive according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: dissolving an aldehyde-modified polyethylene glycol high molecular polymer in a first solvent to obtain component A; dissolving an amino high molecular polymer and a thickener in a second solvent to obtain component B; and mixing the component A and the component B to obtain a hemostatic adhesive.

5. The method for preparing a hemostatic adhesive according to claim 4, characterized in that: The first solvent includes at least one of double distilled water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution; The second solvent includes at least one of double distilled water, phosphate buffer solution, bicarbonate buffer solution, and borate buffer solution.

6. The method for preparing a hemostatic adhesive according to claim 4, characterized in that: The mass concentration of the aldehyde-modified polyethylene glycol polymer in component A is 0.1%-20%; the mass concentration of the amino polymer in component B is 0.01%-30%; and the mass concentration of the thickener in component B is 0.02%-20%.

7. The method for preparing a hemostatic adhesive according to claim 4, characterized in that: The mass concentration of the aldehyde-modified polyethylene glycol polymer in component A is 0.5%-15%; the mass concentration of the amino polymer in component B is 0.05%-10%; and the mass concentration of the thickener in component B is 0.05%-5%.

8. The method for preparing a hemostatic adhesive according to any one of claims 4 to 7, characterized in that: The volume ratio of the component A to the component B is 1:1-5.

9. The method for preparing a hemostatic adhesive according to claim 8, characterized in that: The solid content of the hemostatic adhesive is 1%-30%.

10. An application of a hemostatic adhesive, characterized in that: The hemostatic adhesive according to any one of claims 1 to 3 is used to prepare products for hemostasis and promoting wound healing.

Images